川宁生物
(301301)
| 流通市值：83.21亿 | | | 总市值：300.89亿 |
| 流通股本：6.16亿 | | | 总股本：22.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,456,265,553.38 | 3,195,426,670.39 | 1,523,218,164 | 4,823,335,006.68 |
| 营业收入 | 4,456,265,553.38 | 3,195,426,670.39 | 1,523,218,164 | 4,823,335,006.68 |
| 利息收入 | - | - | 0 | - |
| 已赚保费 | - | - | 0 | - |
| 手续费及佣金收入 | - | - | 0 | - |
| 二、营业总成本 | 3,154,494,351.3 | 2,264,062,909.63 | 1,098,639,822.39 | 3,648,830,039.14 |
| 营业成本 | 2,859,990,249.26 | 2,067,053,173.06 | 998,934,951.95 | 3,300,397,107.76 |
| 利息支出 | - | - | 0 | - |
| 手续费及佣金支出 | - | - | 0 | - |
| 退保金 | - | - | 0 | - |
| 赔付支出净额 | - | - | 0 | - |
| 提取保险合同准备金净额 | - | - | 0 | - |
| 保单红利支出 | - | - | 0 | - |
| 分保费用 | - | - | 0 | - |
| 税金及附加 | 67,497,277.45 | 46,433,467.23 | 19,718,101.89 | 66,645,972.61 |
| 销售费用 | 19,570,247.05 | 11,595,579.59 | 3,847,424.73 | 22,566,486.12 |
| 管理费用 | 120,907,167.54 | 82,490,359.88 | 46,790,092.16 | 143,131,452.65 |
| 研发费用 | 44,066,130.04 | 28,780,545.77 | 16,682,182.7 | 55,258,054.34 |
| 财务费用 | 42,463,279.96 | 27,709,784.1 | 12,667,068.96 | 60,830,965.66 |
| 其中:利息费用 | 35,271,386 | 25,559,064.11 | 15,427,735.95 | 87,778,513.53 |
| 其中:利息收入 | 5,580,050.47 | 3,892,589.09 | 1,756,707.71 | 16,177,909.19 |
| 加:公允价值变动收益 | 644,500 | -224,600 | -519,933.21 | -1,183,970.14 |
| 加:投资收益 | -7,158,473.66 | -6,312,107.86 | -3,065,505.92 | -13,550,746.12 |
| 资产处置收益 | 0 | 0 | - | 1,336,124.94 |
| 资产减值损失(新) | -8,454,398.3 | -8,454,398.3 | 0 | -42,650,783.01 |
| 信用减值损失(新) | 2,330,553.05 | 258,723.71 | 750,535.87 | -6,502,796.67 |
| 其他收益 | 5,582,166.6 | 3,049,150.52 | 1,484,060.65 | 9,446,889.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,294,715,549.77 | 919,680,528.83 | 423,227,499 | 1,121,399,685.69 |
| 加:营业外收入 | 1,072,661.77 | 67,365.46 | 45,395.97 | 1,979,891.33 |
| 减:营业外支出 | 17,866,084.4 | 10,590,765.2 | 1,353,274.92 | 5,668,505.39 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,277,922,127.14 | 909,157,129.09 | 421,919,620.05 | 1,117,711,071.63 |
| 减:所得税费用 | 201,965,048.01 | 142,829,505.33 | 69,293,508.13 | 177,146,075.34 |
| 六、净利润 | 1,075,957,079.13 | 766,327,623.76 | 352,626,111.92 | 940,564,996.29 |
| 持续经营净利润 | 1,075,957,079.13 | 766,327,623.76 | 352,626,111.92 | 940,564,996.29 |
| 终止经营净利润 | - | 0 | 0 | - |
| 归属于母公司股东的净利润 | 1,075,918,531.82 | 766,304,098.5 | 352,614,874.42 | 940,563,998.57 |
| 少数股东损益 | 38,547.31 | 23,525.26 | 11,237.5 | 997.72 |
| (一)基本每股收益 | 0.48 | 0.34 | 0.16 | 0.42 |
| (二)稀释每股收益 | 0.48 | 0.34 | 0.16 | 0.42 |
| 八、其他综合收益 | - | - | 0 | - |
| 归属于母公司股东的其他综合收益 | - | - | 0 | - |
| 九、综合收益总额 | 1,075,957,079.13 | 766,327,623.76 | 352,626,111.92 | 940,564,996.29 |
| 归属于母公司股东的综合收益总额 | 1,075,918,531.82 | 766,304,098.5 | 352,614,874.42 | 940,563,998.57 |
| 归属于少数股东的综合收益总额 | 38,547.31 | 23,525.26 | 11,237.5 | 997.72 |
| 公告日期 | 2024-10-22 | 2024-08-27 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |